Envestnet Asset Management
ALNY icon

Envestnet Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Envestnet Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1M Sell
136,395
-35,402
-21% -$10.7M 0.01% 968
2026
Q1 		$56.8M Buy
171,797
+51,276
+43% +$17.4M 0.02% 744
2025
Q4 		$47.9M Buy
120,521
+1,557
+1% +$689K 0.01% 768
2025
Q3 		$54.2M Buy
118,964
+23,168
+24% +$9.43M 0.02% 735
2025
Q2 		$31.2M Buy
95,796
+23,749
+33% +$6.57M 0.01% 982
2025
Q1 		$19.5M Buy
72,047
+6,033
+9% +$1.55M 0.01% 1208
2024
Q4 		$15.5M Buy
66,014
+34,647
+110% +$9.11M 0.01% 1347
2024
Q3 		$8.63M Buy
31,367
+6,227
+25% +$1.62M ﹤0.01% 1737
2024
Q2 		$6.11M Sell
25,140
-2,295
-8% -$362K ﹤0.01% 1888
2024
Q1 		$4.1M Buy
27,435
+156
+0.6% +$26K ﹤0.01% 2117
2023
Q4 		$5.22M Buy
27,279
+2,709
+11% +$461K ﹤0.01% 1871
2023
Q3 		$4.35M Buy
24,570
+5,727
+30% +$1.09M ﹤0.01% 1894
2023
Q2 		$3.58M Buy
18,843
+3,477
+23% +$689K ﹤0.01% 1908
2023
Q1 		$3.08M Buy
15,366
+1,280
+9% +$269K ﹤0.01% 1925
2022
Q4 		$3.35M Sell
14,086
-3,000
-18% -$640K ﹤0.01% 1833
2022
Q3 		$3.42M Buy
17,086
+2,972
+21% +$567K ﹤0.01% 1738
2022
Q2 		$2.06M Sell
14,114
-17,306
-55% -$2.46M ﹤0.01% 2089
2022
Q1 		$5.13M Sell
31,420
-2,893
-8% -$441K ﹤0.01% 1588
2021
Q4 		$5.82M Buy
34,313
+2,828
+9% +$526K ﹤0.01% 1510
2021
Q3 		$5.94M Buy
31,485
+1,480
+5% +$278K ﹤0.01% 1420
2021
Q2 		$5.09M Buy
30,005
+3,378
+13% +$495K ﹤0.01% 1510
2021
Q1 		$3.76M Buy
26,627
+12,998
+95% +$1.96M ﹤0.01% 1581
2020
Q4 		$1.77M Sell
13,629
-24,953
-65% -$3.33M ﹤0.01% 1831
2020
Q3 		$5.62M Sell
38,582
-1,758
-4% -$250K 0.01% 1106
2020
Q2 		$5.97M Buy
40,340
+31,940
+380% +$4.31M 0.01% 1038
2020
Q1 		$914K Buy
+8,400
New +$970K ﹤0.01% 1869

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Envestnet Asset Management's ALNY Position: Q2 2026 in Review

Envestnet Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 21% in Q2 2026, selling an estimated $10.7M and leaving 136,395 shares worth $41.1M. The position accounts for 0.01% of the portfolio, ranked #968.

Envestnet Asset Management first reported a position in ALNY in Q1 2020 and has held it in 26 quarters since. The position peaked at $56.8M in Q1 2026. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Envestnet Asset Management held 136,395 shares of Alnylam Pharmaceuticals worth $41.1M as of Q2 2026.
  • Envestnet Asset Management sold 35,402 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $10.7M.
  • Alnylam Pharmaceuticals made up 0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #968 holding.
  • Envestnet Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Envestnet Asset Management's Alnylam Pharmaceuticals position peaked at $56.8M in Q1 2026.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.